Dr. Christoph Schröder studied molecular biotechnology at the University of Bielefeld. As a PhD student and researcher, he spent a decade at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) developing antibody microarrays into a robust platform for highly parallel protein analyses. On this basis, he founded Sciomics GmbH together with Dr. Jörg Hoheisel in the spring of 2013 and has been managing director since then. Sciomics develops protein biomarker signatures based on the established platform in the field of oncology and organ failure. In addition to this early-stage development of innovative diagnostics, Sciomics works closely together with renowned research institutes and pharmaceutical companies within the scope of a service business.